220 related articles for article (PubMed ID: 23649683)
1. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
2. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
3. Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Wachsberger PR; Lawrence RY; Liu Y; Xia X; Andersen B; Dicker AP
J Neurooncol; 2011 Nov; 105(2):181-90. PubMed ID: 21516367
[TBL] [Abstract][Full Text] [Related]
4. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
[TBL] [Abstract][Full Text] [Related]
6. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Liu HL; Huang CY; Chen JY; Wang HY; Chen PY; Wei KC
PLoS One; 2014; 9(12):e114311. PubMed ID: 25490097
[TBL] [Abstract][Full Text] [Related]
8. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Ma J; Li S; Reed K; Guo P; Gallo JM
J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
[TBL] [Abstract][Full Text] [Related]
10. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Zhou Q; Guo P; Wang X; Nuthalapati S; Gallo JM
J Pharmacol Exp Ther; 2007 Apr; 321(1):265-75. PubMed ID: 17259446
[TBL] [Abstract][Full Text] [Related]
12. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Zhou Q; Guo P; Gallo JM
Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
17. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
18. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Carcaboso AM; Elmeliegy MA; Shen J; Juel SJ; Zhang ZM; Calabrese C; Tracey L; Waters CM; Stewart CF
Cancer Res; 2010 Jun; 70(11):4499-508. PubMed ID: 20460504
[TBL] [Abstract][Full Text] [Related]
20. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]